Physician profile
Stephen W Stocking
NPI 1104903392
$4,969.76
in general payments reported to CMS, 2019-2025
35 companies · $1,105 in 2025
The $1,105 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $593 · 2022: $548 · 2023: $1,362 · 2024: $1,363 · 2025: $1,105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,829.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,829.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $710.51 | 2021-2025 | Dovato, Cabenuva, Apretude |
| Bayer Healthcare Pharmaceuticals INC. | $590.31 | 2022-2025 | |
| Novo Nordisk INC | $551.03 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $548.28 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $305.74 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Sumitomo Pharma America, INC. | $197.59 | 2023-2025 | Gemtesa |
| Pfizer INC. | $182.26 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $163.45 | 2021-2024 | Xifaxan |
| Glaxosmithkline, LLC. | $154.60 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Gilead Sciences, INC. | $151.86 | 2023-2025 | Biktarvy |
| Amgen INC. | $135.09 | 2021-2025 | Repatha, Otezla, Repatha |
| Abbott Laboratories | $127.22 | 2021-2024 | Freestyle Libre 3 |
| Abbvie INC. | $117.27 | 2021-2025 | |
| Dexcom, INC. | $114.70 | 2024-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $100.13 | 2021-2025 | Veozah |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $89.55 | 2023-2025 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $72.07 | 2022-2024 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.35 | 2024-2025 | Jardiance, Ofev |
| Merck Sharp & Dohme LLC | $64.90 | 2021-2023 | Verquvo, Belsomra |
| Ardelyx, INC. | $60.38 | 2024 | Ibsrela |
| Teleflex LLC | $59.26 | 2024 | Urolift |
| Janssen Biotech, INC. | $50.70 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $40.69 | 2021 | |
| Amarin Pharma, INC. | $39.95 | 2021 | |
| Corcept Therapeutics | $35.93 | 2025 | Korlym |
| Kowa Pharmaceuticals America, INC. | $35.17 | 2023-2025 | Livalo, Seglentis, Zoryve |
| Corium, LLC | $33.68 | 2023 | Adlarity |
| Sanofi-Aventis U.S. LLC | $28.51 | 2021-2023 | |
| Alexion Pharmaceuticals, INC. | $26.65 | 2022 | |
| Phathom Pharmaceuticals, INC. | $22.59 | 2025 | Voquezna |
| Xeris Pharmaceuticals, INC. | $20.52 | 2023 | Gvoke Hypopen |
| Medtronic, INC. | $18.56 | 2023 | Minimed 780g |
| Insmed, INC. | $18.47 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $18.01 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Stocking listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.